To our knowledge, this is the first study to evaluate the estimated survival as well as estimated YLL in patients treated with targeted therapies for advanced NSCLC that harbor actionable oncogenic mutations including EGFR, ALK, ROS1, MET, RET, HER2, BRAF, and NTRK. Here, ROS1 is linked to non-small cell lung carcinoma.